Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab : a multicenter retrospective study
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Annals of hematology - (2024) vom: 16. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakamura, Naokazu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Daratumumab |
|---|
| Anmerkungen: |
Date Revised 16.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00277-024-05705-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369816986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369816986 | ||
| 003 | DE-627 | ||
| 005 | 20240317233403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-024-05705-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1333.xml |
| 035 | |a (DE-627)NLM369816986 | ||
| 035 | |a (NLM)38492020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakamura, Naokazu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab |b a multicenter retrospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Daratumumab | |
| 650 | 4 | |a Elotuzumab | |
| 650 | 4 | |a Immune microenvironment | |
| 650 | 4 | |a Multiple myeloma | |
| 700 | 1 | |a Arima, Nobuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takakuwa, Teruhito |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Imada, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Hotta, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchida, Shin-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Uoshima, Nobuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Shimura, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kosugi, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Yagi, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshihara, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamura, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Hanamoto, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shibayama, Hirohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hosen, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Tomoki |e verfasserin |4 aut | |
| 700 | 1 | |a Shimazaki, Chihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takaori-Kondo, Akifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroda, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumura, Itaru |e verfasserin |4 aut | |
| 700 | 1 | |a Hino, Masayuki |e verfasserin |4 aut | |
| 700 | 0 | |a Kansai Myeloma Forum |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g (2024) vom: 16. März |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-024-05705-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 03 | ||